Cargando…

Tolvaptan activates the Nrf2/HO-1 antioxidant pathway through PERK phosphorylation

Tolvaptan, a vasopressin type 2 receptor antagonist initially developed to increase free-water diuresis, has been approved for the treatment of autosomal dominant polycystic kidney disease in multiple countries. Furthermore, tolvaptan has been shown to improve the renal functions in rodent models of...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiki, Tamami, Ando, Fumiaki, Murakami, Kana, Isobe, Kiyoshi, Mori, Takayasu, Susa, Koichiro, Nomura, Naohiro, Sohara, Eisei, Rai, Tatemitsu, Uchida, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592894/
https://www.ncbi.nlm.nih.gov/pubmed/31239473
http://dx.doi.org/10.1038/s41598-019-45539-8

Ejemplares similares